#USA #Tampa #IFx-2.0 #HURA #TBS-2025

TuHURA Biosciences Announces Upcoming Participations at Investor Conferences

TuHURA Biosciences, Inc. (NASDAQ: HURA) is set to make a significant mark in the immuno-oncology sphere with its upcoming appearances at the Citizens Life Science Conference and the Leerink Global Healthcare Conference. The events, scheduled for early March 2026, will feature TuHURA’s President and CEO, Dr. James Bianco, who will represent the company’s mission to transform cancer treatment.

Key Conference Details

Citizens Life Science Conference

• - Date: Tuesday, March 10, 2026
• - Time: 4:00 PM ET
• - Access: Interested participants can register here to view the presentation live. A recorded webcast will be available for later viewing on TuHURA's corporate website.

Leerink Global Healthcare Conference

• - Date: Wednesday, March 11, 2026
• - Format: TuHURA will offer opportunities for one-on-one meetings with investors.
• - Meeting Request: Those interested should get in touch with their Leerink representatives for meeting arrangements.

About TuHURA Biosciences

TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company with a focus on developing cutting-edge therapies to address primary and acquired resistance to cancer immunotherapy—the key reasons many cancer treatments fail. The company’s flagship product, IFx-2.0, aims to empower patients by overcoming these resistance challenges, providing hope where traditional treatments have faltered.

Currently, TuHURA is conducting a pivotal Phase 3 trial comparing IFx-2.0 as an adjunctive therapy to Keytruda® (pembrolizumab), targeting patients with advanced or metastatic Merkel Cell Carcinoma.

In addition to IFx-2.0, TuHURA has strengthened its pipeline with TBS-2025, a monoclonal antibody designed to inhibit VISTA and currently progressing towards Phase 2 trials for treating mutNPM1 r/r AML. This product was acquired during the merger with Kineta Inc. in June 2025.

TuHURA is also at the forefront of innovation by applying its Delta Opioid Receptor technology to develop unique bi-specific antibody drug conjugates and antibody peptide conjugates aimed at combating immune suppression in tumors. This dual approach hopes to enhance the efficacy of both checkpoint inhibitors and cellular therapies by preventing T cell exhaustion.

Looking Ahead

These conferences present an invaluable opportunity for TuHURA Biosciences to engage with investors and communicate its visionary approach to combating cancer. With an emphasis on collaboration and innovation, TuHURA is poised to lead in the development of solutions that could potentially reshape the landscape of cancer treatment.

For more detailed information on upcoming events and TuHURA's pipeline, visit their official website or connect via their social media platforms including Facebook, X, and LinkedIn.